29060/433.

Study characteristics
Methods	Design: parallel Duration: 8 weeks Assessment: baseline and post‐intervention Country: Belgium
Participants	Pain condition: fibromyalgia Population: people with fibromyalgia and depressive symptoms Minimum pain intensity: ≥ 4 on 0‐10 VAS Inclusion criteria Fibromyalgia meeting ACR criteria ≥ 4 on 0‐10 pain intensity VAS Concomitant depressive symptoms Exclusion criteria Physical health comorbidities Psychiatric disorders Total participants randomised: 52 Age in years (mean): 45 Gender: 12/45 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 26 Paroxetine 20 mg n = 26 SSRI Fixed dose
Outcomes	AEs SAEs Withdrawal
Missing data methods	ITT but no method reported
Funding source	Pharamaceutical: GlaxoSmithKline
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedures not specified
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information given regarding blinding procedures
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Self‐reported outcomes from participants but unsure of blinding measures
Incomplete outcome data (attrition bias) All outcomes	High risk	Use ITT for primary outcome but don't report imputation method. Completer‐only analysis for the secondary outcomes Attrition Total: 13/52 (25.0%) Placebo: 5/26 (19.2%) Paroxetine 20 mg: 8/26 (30.8%)
Selective reporting (reporting bias)	High risk	State a number of measures that they will collect but don't report findings for (Abnormal Involuntary Movement Scale, fatigue VAS). No protocol, no publication
Other bias	High risk	Not published ‐ just a scientific summary on GSK registry. Trial ran in 1995 but only posted in 2005